Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts.
<h4>Background</h4> <p>Cardiovascular disease (CVD) influences phenotypic variation in Parkinson’s disease (PD), and is usually an indication for statin therapy. It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriatel...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2016
|
| _version_ | 1797057945029050368 |
|---|---|
| author | Swallow, D Lawton, M Grosset, K Malek, N Klein, J Baig, F Ruffmann, C Bajaj, N Barker, R Ben-Shlomo, Y Burn, D Foltynie, T Morris, H Williams, N Wood, N Hu, M Grosset, D |
| author_facet | Swallow, D Lawton, M Grosset, K Malek, N Klein, J Baig, F Ruffmann, C Bajaj, N Barker, R Ben-Shlomo, Y Burn, D Foltynie, T Morris, H Williams, N Wood, N Hu, M Grosset, D |
| author_sort | Swallow, D |
| collection | OXFORD |
| description | <h4>Background</h4> <p>Cardiovascular disease (CVD) influences phenotypic variation in Parkinson’s disease (PD), and is usually an indication for statin therapy. It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriately.</p> <h4>Objectives</h4> <p>To quantify vascular risk and statin use in recent onset PD, and examine the relationship between vascular risk, PD severity and phenotype.</p> <h4>Methods</h4> <p>Cardiovascular risk was quantified using the QRISK2 calculator (high ≥20%, medium ≥10 and <20%, low risk <10%). Motor severity and phenotype were assessed using the Movement Disorder Society Unified PD Rating Scale (UPDRS) and cognition by the Montreal cognitive assessment.</p> <h4>Results</h4> <p>In 2,909 individuals with recent onset PD, the mean age was 67.5 years (SD 9.3), 63.5% were male, and mean disease duration was 1.3 years (SD 0.9). 33.8% of cases had high vascular risk, 28.7% medium risk, and 22.3% low risk, while 15.2% of cases had established CVD. Increasing vascular risk and CVD were associated with older age (p<0.001), worse motor score (p<0.001), more cognitive impairment (p<0.001), and worse motor phenotype (p=0.021). Statins were prescribed in 37.2% with high vascular risk, 15.1% with medium vascular risk, and 6.5% with low vascular risk, which compared with statin usage in 75.3% of those with CVD.</p> <h4>Conclusion</h4> <p>Over 60% of recent onset PD patients have high or medium cardiovascular risk (meriting statin usage), which is associated with a worse motor and cognitive phenotype. Statins are underused in these patients, compared to those with vascular disease, which is a missed opportunity for preventive treatment.</p> |
| first_indexed | 2024-03-06T19:43:34Z |
| format | Journal article |
| id | oxford-uuid:217bca03-3f87-4d86-93fd-424977849ae7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:43:34Z |
| publishDate | 2016 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:217bca03-3f87-4d86-93fd-424977849ae72022-03-26T11:33:47ZStatins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:217bca03-3f87-4d86-93fd-424977849ae7EnglishSymplectic Elements at OxfordBMJ Publishing Group2016Swallow, DLawton, MGrosset, KMalek, NKlein, JBaig, FRuffmann, CBajaj, NBarker, RBen-Shlomo, YBurn, DFoltynie, TMorris, HWilliams, NWood, NHu, MGrosset, D <h4>Background</h4> <p>Cardiovascular disease (CVD) influences phenotypic variation in Parkinson’s disease (PD), and is usually an indication for statin therapy. It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriately.</p> <h4>Objectives</h4> <p>To quantify vascular risk and statin use in recent onset PD, and examine the relationship between vascular risk, PD severity and phenotype.</p> <h4>Methods</h4> <p>Cardiovascular risk was quantified using the QRISK2 calculator (high ≥20%, medium ≥10 and <20%, low risk <10%). Motor severity and phenotype were assessed using the Movement Disorder Society Unified PD Rating Scale (UPDRS) and cognition by the Montreal cognitive assessment.</p> <h4>Results</h4> <p>In 2,909 individuals with recent onset PD, the mean age was 67.5 years (SD 9.3), 63.5% were male, and mean disease duration was 1.3 years (SD 0.9). 33.8% of cases had high vascular risk, 28.7% medium risk, and 22.3% low risk, while 15.2% of cases had established CVD. Increasing vascular risk and CVD were associated with older age (p<0.001), worse motor score (p<0.001), more cognitive impairment (p<0.001), and worse motor phenotype (p=0.021). Statins were prescribed in 37.2% with high vascular risk, 15.1% with medium vascular risk, and 6.5% with low vascular risk, which compared with statin usage in 75.3% of those with CVD.</p> <h4>Conclusion</h4> <p>Over 60% of recent onset PD patients have high or medium cardiovascular risk (meriting statin usage), which is associated with a worse motor and cognitive phenotype. Statins are underused in these patients, compared to those with vascular disease, which is a missed opportunity for preventive treatment.</p> |
| spellingShingle | Swallow, D Lawton, M Grosset, K Malek, N Klein, J Baig, F Ruffmann, C Bajaj, N Barker, R Ben-Shlomo, Y Burn, D Foltynie, T Morris, H Williams, N Wood, N Hu, M Grosset, D Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. |
| title | Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. |
| title_full | Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. |
| title_fullStr | Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. |
| title_full_unstemmed | Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. |
| title_short | Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. |
| title_sort | statins are underused in recent onset parkinson s disease with increased vascular risk findings from the uk tracking parkinson s and oxford parkinson s disease centre opdc discovery cohorts |
| work_keys_str_mv | AT swallowd statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT lawtonm statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT grossetk statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT malekn statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT kleinj statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT baigf statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT ruffmannc statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT bajajn statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT barkerr statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT benshlomoy statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT burnd statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT foltyniet statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT morrish statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT williamsn statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT woodn statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT hum statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts AT grossetd statinsareunderusedinrecentonsetparkinsonsdiseasewithincreasedvascularriskfindingsfromtheuktrackingparkinsonsandoxfordparkinsonsdiseasecentreopdcdiscoverycohorts |